MX351727B - Integracion especifica de sitio. - Google Patents

Integracion especifica de sitio.

Info

Publication number
MX351727B
MX351727B MX2014015612A MX2014015612A MX351727B MX 351727 B MX351727 B MX 351727B MX 2014015612 A MX2014015612 A MX 2014015612A MX 2014015612 A MX2014015612 A MX 2014015612A MX 351727 B MX351727 B MX 351727B
Authority
MX
Mexico
Prior art keywords
specific integration
site
host cells
ssi
cho
Prior art date
Application number
MX2014015612A
Other languages
English (en)
Other versions
MX2014015612A (es
Inventor
Rance James
Young Robert
J Agostino Michael
Moffat Mark
Zhang Lin
Zhang Baohong
Original Assignee
Lonza Biologics Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lonza Biologics Plc filed Critical Lonza Biologics Plc
Publication of MX2014015612A publication Critical patent/MX2014015612A/es
Publication of MX351727B publication Critical patent/MX351727B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a células hospederas de integración específica de sitio (SSI) estables y de alta producción, por ejemplo células hospederas derivadas de ovario de hámster chino (CHO), a métodos para producirlas y para utilizarlas.
MX2014015612A 2012-06-22 2013-06-20 Integracion especifica de sitio. MX351727B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261663147P 2012-06-22 2012-06-22
EP12185330.3A EP2711428A1 (en) 2012-09-21 2012-09-21 Site-specific integration
PCT/EP2013/062859 WO2013190032A1 (en) 2012-06-22 2013-06-20 Site-specific integration

Publications (2)

Publication Number Publication Date
MX2014015612A MX2014015612A (es) 2015-07-14
MX351727B true MX351727B (es) 2017-10-26

Family

ID=46888327

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015612A MX351727B (es) 2012-06-22 2013-06-20 Integracion especifica de sitio.

Country Status (19)

Country Link
US (2) US10280436B2 (es)
EP (2) EP2711428A1 (es)
JP (1) JP6053923B2 (es)
KR (1) KR101761709B1 (es)
CN (1) CN104379753B (es)
AU (1) AU2013279333C1 (es)
BR (1) BR112014032299B1 (es)
CA (1) CA2876280C (es)
DK (1) DK2864489T3 (es)
EA (1) EA034039B1 (es)
ES (1) ES2629509T3 (es)
HK (1) HK1202580A1 (es)
IL (1) IL236347A0 (es)
IN (1) IN2014MN02518A (es)
MX (1) MX351727B (es)
PL (1) PL2864489T3 (es)
SG (1) SG11201408576QA (es)
TW (1) TWI523946B (es)
WO (1) WO2013190032A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
PL3289092T3 (pl) 2015-04-27 2020-07-13 Momenta Pharmaceuticals, Inc. Sposób wytwarzania białka terapeutycznego
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
WO2017132376A1 (en) 2016-01-27 2017-08-03 Just Biotherapeutics, Inc. Hybrid promoter and uses thereof
AU2017253240B2 (en) * 2016-04-20 2024-07-04 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of an expression-enhancing locus
SG11201807885PA (en) 2016-04-20 2018-10-30 Regeneron Pharma Compositions and methods for making antibodies based on use of expression-enhancing loci
CN111372946A (zh) * 2017-02-17 2020-07-03 隆萨有限公司 难以表达的蛋白质的多位点特异性整合细胞
WO2018150271A1 (en) 2017-02-17 2018-08-23 Lonza Ltd. Mammalian cells for producing adeno-associated viruses
GB201703418D0 (en) * 2017-03-03 2017-04-19 Ge Healthcare Bio Sciences Ab Method for cell line development
CA3056182A1 (en) 2017-03-16 2018-09-20 Pfizer Inc. Tyrosine prototrophy
CN107557390A (zh) * 2017-09-18 2018-01-09 江南大学 一种筛选cho细胞系高表达位点的方法
WO2020072480A1 (en) * 2018-10-01 2020-04-09 Lonza Ltd Ssi cells with predictable and stable transgene expression and methods of formation
AU2019403279A1 (en) * 2018-12-21 2021-07-01 Genentech, Inc. Targeted integration of nucleic acids
JP7522100B2 (ja) * 2019-04-02 2024-07-24 中外製薬株式会社 標的特異的な外来遺伝子の導入方法
WO2021094461A1 (en) 2019-11-14 2021-05-20 Lonza Ltd Methods of cell selection
KR102335242B1 (ko) 2020-05-22 2021-12-02 인천대학교 산학협력단 Fer1L4 유전자에 부위-특이적 통합된 RMCE 랜딩 패드를 포함하는 CHO 세포
EP4189093A1 (en) 2020-07-30 2023-06-07 Pfizer Inc. Cells having gene duplications and uses thereof
CA3227875A1 (en) 2021-08-02 2023-02-09 Pfizer Inc. Improved expression vectors and uses thereof
WO2023148598A1 (en) 2022-02-02 2023-08-10 Pfizer Inc. Cysteine prototrophy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
WO1998048005A1 (en) 1997-04-24 1998-10-29 University Of Washington Targeted gene modification by parvoviral vectors
WO2006007850A1 (en) * 2004-07-20 2006-01-26 Symphogen A/S Anti-rhesus d recombinant polyclonal antibody and methods of manufacture
JP4665115B2 (ja) * 2004-08-06 2011-04-06 独立行政法人理化学研究所 骨・関節疾患感受性遺伝子およびその用途
CA2615532C (en) 2005-07-26 2016-06-28 Sangamo Biosciences, Inc. Targeted integration and expression of exogenous nucleic acid sequences

Also Published As

Publication number Publication date
MX2014015612A (es) 2015-07-14
SG11201408576QA (en) 2015-03-30
US20150167020A1 (en) 2015-06-18
US11326185B2 (en) 2022-05-10
EA034039B1 (ru) 2019-12-20
EP2864489B1 (en) 2017-03-29
AU2013279333A1 (en) 2015-02-12
TW201420762A (zh) 2014-06-01
EP2864489A1 (en) 2015-04-29
US10280436B2 (en) 2019-05-07
CA2876280A1 (en) 2013-12-27
US20190119702A1 (en) 2019-04-25
EP2711428A1 (en) 2014-03-26
AU2013279333C1 (en) 2017-08-31
AU2013279333B2 (en) 2017-03-30
JP6053923B2 (ja) 2016-12-27
DK2864489T3 (en) 2017-07-17
HK1202580A1 (en) 2015-10-02
IL236347A0 (en) 2015-02-26
KR20150029693A (ko) 2015-03-18
ES2629509T3 (es) 2017-08-10
TWI523946B (zh) 2016-03-01
WO2013190032A1 (en) 2013-12-27
CN104379753A (zh) 2015-02-25
CA2876280C (en) 2018-02-06
PL2864489T3 (pl) 2017-09-29
BR112014032299B1 (pt) 2021-09-21
CN104379753B (zh) 2020-06-09
BR112014032299A2 (pt) 2017-08-01
JP2015519914A (ja) 2015-07-16
IN2014MN02518A (es) 2015-07-17
AU2013279333B9 (en) 2017-06-29
KR101761709B1 (ko) 2017-07-26
EA201590068A1 (ru) 2015-04-30

Similar Documents

Publication Publication Date Title
MX351727B (es) Integracion especifica de sitio.
ZA202201361B (en) Methods and compositions comprising purified recombinant polypeptides
PH12015501000A1 (en) Anti-notch3 antibodies and antibody-drug conjugates
UY34824A (es) Nucleósidos de espirooxetano de uracilo
EP2877490A4 (en) CLIENTS, CONJUGATES AND USES THEREOF
MX2016008448A (es) Conjugados de var2csa-farmaco.
EP2825000B8 (en) Self-shielded vertical proton linear accelerator for proton-therapy
SG10201811017QA (en) Novel antibody frameworks
UY34582A (es) Anticuerpos anti-cxcr3
EP3026674A4 (en) Composition for forming solar cell electrode, and electrode produced from composition
TR201905787T4 (tr) Liyofilize TAT-NR2B9C formülasyonu.
HK1223469A1 (zh) 地理、區段、唯分布式計算系統
MX349485B (es) Composiciones de higiene bucal.
MX2016002217A (es) Compuestos con actividad pesticida.
UY34677A (es) Imidazopiridazinas sustituidas
MY175703A (en) Tablets with improved acceptance and good storage stability
GB201220835D0 (en) S/V.D.R.-;system
CL2012003477S1 (es) Perno de seguridad
UA89695U (en) Lisoverm, complex antiparasitic composition
MX2016001694A (es) Formulacion de vacuna de sacarido.
AU2013902587A0 (en) Frameworks, devices and methodologies configured for enabling collaborative content generation
UA78285U (en) N- methylmorpholinium 4-(4-ethoxyphenyl)-2-oxo-5-cyano-1,2,3,4-tetrahydropyridine-6-thiolate
TH1401001666B (th) ระบบและวิธีการรีมอดูเลชันแบบอะซิงโครนัสโดยการปรับ i/q เชิงปรับตัว
UA90689U (uk) Комплексний протипаразитарний препарат "лактоверм"
UA78284U (en) 5,11- dibenzyl -8-thioxo-13-(2-chlorophenyl)-3,5,7,11- tetraazatricyclo[7.3.1.02,7]tridec-2-ene-1,9-dicarbonitrile

Legal Events

Date Code Title Description
FG Grant or registration